Entact Bio

Entact Bio is an early-stage biotech innovator developing a new therapeutic modality focused on targeted protein enhancement, contrasting with the dominant protein degradation field. Its core technology, the Encompass platform, designs bifunctional small molecules (ENTACs) that recruit specific DUB enzymes to stabilize, relocate, or otherwise enhance the function of disease-relevant proteins. The company is advancing a pipeline of preclinical programs, backed by experienced leadership and scientific founders, to address previously undruggable targets in areas like oncology and immunology. As a private, pre-revenue entity, its success hinges on validating its novel platform and translating its science into clinical candidates.

Encompass™ platform for discovering ENTACs (Enhancement-Targeting Chimeras), which are bifunctional small molecules that recruit specific deubiquitylase (DUB) enzymes to enhance the function, stability, or localization of target proteins.

Entact is a pioneer in targeted protein enhancement, a niche within the broader proximity-inducing modality field dominated by protein degraders (PROTACs). While first-in-class for DUB-recruiting enhancers, it faces potential competition from other biotechs exploring similar concepts and from large pharma with internal targeted protein modulation efforts. Its success depends on establishing a strong IP position and first-mover validation.